Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Blood
Naval DaverHagop Kantarjian

Abstract

The advent of small molecule-based targeted therapy has improved the treatment of both acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a common theme. The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain. FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid leukemia (AML). The occurrence of the ATP-binding site and activation loop mutations confers varying degrees of resistance to the individual FLT3 inhibitors. Second-generation FLT3 inhibitors such as crenolanib may overcome the resistance of these mutations. Furthermore, nonmutational mechanisms of resistance such as prosurvival pathways and bone marrow signaling may be upregulated in FLT3 inhibitor-resistant AML with secondary kinase domain mutations. More recently, point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute promyelocytic leukemia, and the BH3-mimetic ABT199 in lymphoma have been identified. In chronic myeloid leukemia, the emergence of tyrosine kinase domain mutations has historically been the dominant mechanism of resistance. The early identification of secondar...Continue Reading

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Nov 12, 2003·The Journal of Experimental Medicine·Marcel SpaargarenSteven T Pals
Nov 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yiguo HuShaoguang Li
Nov 3, 2007·The Lancet Oncology·Jane F Apperley
Nov 29, 2008·Science·Charles G MullighanJames R Downing
Dec 24, 2008·Nature Reviews. Cancer·Jianming ZhangNathanael S Gray
Jul 7, 2009·Hematology/oncology Clinics of North America·Dragan Jevremovic, David S Viswanatha
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley

❮ Previous
Next ❯

Citations

Oct 21, 2015·Nature Reviews. Clinical Oncology·Michael W SchmittJesse J Salk
Feb 2, 2016·Future Oncology·Harinder GillYok-Lam Kwong
Nov 12, 2015·Biochimica Et Biophysica Acta·Nicole S NicholasAlan G Ramsay
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Feb 26, 2016·Expert Review of Hematology·Naval DaverFarhad Ravandi
Mar 31, 2016·International Journal of Molecular Sciences·Harinder GillYok-Lam Kwong
Oct 16, 2016·Best Practice & Research. Clinical Haematology·Deepa Jeyakumar, Susan O'Brien
Apr 7, 2017·Current Treatment Options in Oncology·Aaron RonsonJacob M Rowe
Apr 12, 2017·Current Hematologic Malignancy Reports·Cecilia C S Yeung, Jerald Radich
Dec 12, 2017·The Journal of Clinical Investigation·Jolieke G van OosterwijkSharyn D Baker
Sep 25, 2015·Biomarker Insights·Il-Kang Na, Philipp le Coutre
Oct 27, 2017·Expert Review of Hematology·Marlise R Luskin, Daniel J DeAngelo
Jan 20, 2020·Molecular Oncology·Silvia WaldeckNikolas von Bubnoff
Sep 20, 2017·Proceedings of the National Academy of Sciences of the United States of America·Laura Z RassentiCarlo M Croce
Mar 10, 2020·The Journal of Clinical Investigation·LaQuita M JonesCraig J Thomas
Feb 28, 2020·International Journal of Molecular Sciences·Stephen S Y Lam, Anskar Y H Leung
Jan 18, 2019·Nature Communications·Haijiao ZhangJeffrey W Tyner
Dec 4, 2016·Hematology·Courtney D DiNardo, Jorge E Cortes
May 13, 2020·Journal of Experimental & Clinical Cancer Research : CR·Doh Yu HwangYoo Hong Min
Feb 26, 2019·Therapeutic Advances in Hematology·Nicholas J ShortNaval Daver
Aug 19, 2016·Cancer Discovery·Michael W M KühnScott A Armstrong
Feb 6, 2020·Cancer Discovery·Nicholas J ShortNaval Daver
Nov 28, 2019·Cancer Discovery·Anjali CremerKimberly Stegmaier
Apr 22, 2017·Molecular Cancer Therapeutics·Carly T CampbellScott R Daigle
Feb 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xuejie JiangBing Z Carter

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved